@article{mo_jiang_sun_gu_2015, title={ATP-responsive DNA-graphene hybrid nanoaggregates for anticancer drug delivery}, volume={50}, ISSN={["1878-5905"]}, DOI={10.1016/j.biomaterials.2015.01.053}, abstractNote={Stimuli-triggered drug delivery systems are primarily focused on the applications of the tumor microenvironmental or cellular physiological cues to enhance the release of drugs at the target site. In this study, we applied adenosine-5′-triphosphate (ATP), the primary “energy molecule”, as a trigger for enhanced release of preloaded drugs responding to the intracellular ATP concentration that is significantly higher than the extracellular level. A new ATP-responsive anticancer drug delivery strategy utilizing DNA-graphene crosslinked hybrid nanoaggregates as carriers was developed for controlled release of doxorubicin (DOX), which consists of graphene oxide (GO), two single-stranded DNA (ssDNA, denoted as DNA1 and DNA2) and ATP aptamer. The single-stranded DNA1 and DNA2 together with the ATP aptamer serve as the linkers upon hybridization for controlled assembly of the DNA-GO nanoaggregates, which effectively inhibited the release of DOX from the GO nanosheets. In the presence of ATP, the responsive formation of the ATP/ATP aptamer complex causes the dissociation of the aggregates, which promoted the release of DOX in the environment with a high ATP concentration such as cytosol compared with that in the ATP-deficient extracellular fluid. This supports the development of a novel ATP-responsive platform for targeted on-demand delivery of anticancer drugs inside specific cells.}, journal={BIOMATERIALS}, author={Mo, Ran and Jiang, Tianyue and Sun, Wujin and Gu, Zhen}, year={2015}, month={May}, pages={67–74} }
 @article{mo_jiang_disanto_tai_gu_2014, title={ATP-triggered anticancer drug delivery}, volume={5}, ISSN={["2041-1723"]}, DOI={10.1038/ncomms4364}, abstractNote={Stimuli-triggered drug delivery systems have been increasingly used to promote physiological specificity and on-demand therapeutic efficacy of anticancer drugs. Here we utilize adenosine-5'-triphosphate (ATP) as a trigger for the controlled release of anticancer drugs. We demonstrate that polymeric nanocarriers functionalized with an ATP-binding aptamer-incorporated DNA motif can selectively release the intercalating doxorubicin via a conformational switch when in an ATP-rich environment. The half-maximal inhibitory concentration of ATP-responsive nanovehicles is 0.24 μM in MDA-MB-231 cells, a 3.6-fold increase in the cytotoxicity compared with that of non-ATP-responsive nanovehicles. Equipped with an outer shell crosslinked by hyaluronic acid, a specific tumour-targeting ligand, the ATP-responsive nanocarriers present an improvement in the chemotherapeutic inhibition of tumour growth using xenograft MDA-MB-231 tumour-bearing mice. This ATP-triggered drug release system provides a more sophisticated drug delivery system, which can differentiate ATP levels to facilitate the selective release of drugs.}, journal={NATURE COMMUNICATIONS}, author={Mo, Ran and Jiang, Tianyue and DiSanto, Rocco and Tai, Wanyi and Gu, Zhen}, year={2014}, month={Mar} }
 @article{sun_jiang_lu_reiff_mo_gu_2014, title={Cocoon-Like Self-Degradable DNA Nanoclew for Anticancer Drug Delivery}, volume={136}, ISSN={["0002-7863"]}, DOI={10.1021/ja5088024}, abstractNote={A bioinspired cocoon-like anticancer drug delivery system consisting of a deoxyribonuclease (DNase)-degradable DNA nanoclew (NCl) embedded with an acid-responsive DNase I nanocapsule (NCa) was developed for targeted cancer treatment. The NCl was assembled from a long-chain single-stranded DNA synthesized by rolling-circle amplification (RCA). Multiple GC-pair sequences were integrated into the NCl for enhanced loading capacity of the anticancer drug doxorubicin (DOX). Meanwhile, negatively charged DNase I was encapsulated in a positively charged acid-degradable polymeric nanogel to facilitate decoration of DNase I into the NCl by electrostatic interactions. In an acidic environment, the activity of DNase I was activated through the acid-triggered shedding of the polymeric shell of the NCa, resulting in the cocoon-like self-degradation of the NCl and promoting the release of DOX for enhanced therapeutic efficacy.}, number={42}, journal={JOURNAL OF THE AMERICAN CHEMICAL SOCIETY}, author={Sun, Wujin and Jiang, Tianyue and Lu, Yue and Reiff, Margaret and Mo, Ran and Gu, Zhen}, year={2014}, month={Oct}, pages={14722–14725} }
 @misc{mo_jiang_di_tai_gu_2014, title={Emerging micro-and nanotechnology based synthetic approaches for insulin delivery}, volume={43}, ISSN={["1460-4744"]}, DOI={10.1039/c3cs60436e}, abstractNote={Insulin is essential for type 1 and advanced type 2 diabetics to maintain blood glucose levels and prolong lives. The traditional administration requires frequent subcutaneous insulin injections that are associated with poor patient compliance, including pain, local tissue necrosis, infection, and nerve damage. Taking advantage of emerging micro- and nanotechnologies, numerous alternative strategies integrated with chemical approaches for insulin delivery have been investigated. This review outlines recent developments in the controlled delivery of insulin, including oral, nasal, pulmonary, transdermal, subcutaneous and closed-loop insulin delivery. Perspectives from new materials, formulations and devices at the micro- or nano-scales are specifically surveyed. Advantages and limitations of current delivery methods, as well as future opportunities and challenges are also discussed.}, number={10}, journal={CHEMICAL SOCIETY REVIEWS}, author={Mo, Ran and Jiang, Tianyue and Di, Jin and Tai, Wanyi and Gu, Zhen}, year={2014}, pages={3595–3629} }
 @article{mo_jiang_gu_2014, title={Enhanced Anticancer Efficacy by ATP-Mediated Liposomal Drug Delivery}, volume={53}, ISSN={["1521-3773"]}, DOI={10.1002/anie.201400268}, abstractNote={A liposome-based co-delivery system composed of a fusogenic liposome encapsulating ATP-responsive elements with chemotherapeutics and a liposome containing ATP was developed for ATP-mediated drug release triggered by liposomal fusion. The fusogenic liposome had a protein-DNA complex core containing an ATP-responsive DNA scaffold with doxorubicin (DOX) and could release DOX through a conformational change from the duplex to the aptamer/ATP complex in the presence of ATP. A cell-penetrating peptide-modified fusogenic liposomal membrane was coated on the core, which had an acid-triggered fusogenic potential with the ATP-loaded liposomes or endosomes/lysosomes. Directly delivering extrinsic liposomal ATP promoted the drug release from the fusogenic liposome in the acidic intracellular compartments upon a pH-sensitive membrane fusion and anticancer efficacy was enhanced both in vitro and in vivo.}, number={23}, journal={ANGEWANDTE CHEMIE-INTERNATIONAL EDITION}, author={Mo, Ran and Jiang, Tianyue and Gu, Zhen}, year={2014}, month={Jun}, pages={5815–5820} }
 @article{tai_mo_lu_jiang_gu_2014, title={Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs}, volume={35}, ISSN={["1878-5905"]}, DOI={10.1016/j.biomaterials.2014.05.004}, abstractNote={A graft copolymer with pendant drug segments can fold into nanostructures in a protein folding-like manner. The graft copolymer is constructed by directly polymerizing γ-camptothecin-glutamate N-carboxyanhydride (Glu(CPT)-NCA) on multiple sites of poly(ethylene glycol) (PEG)-based main chain via the ring open polymerization (ROP). The "purely" conjugated anticancer agent camptothecin (CPT) is hydrophobic and serves as the principal driving force during the folding process. When exposed to water, the obtained copolymer, together with doxorubicin (Dox), another anticancer agent, can fold into monodispersed nanocarriers (with a diameter of around 50 nm) for dual-drug delivery. Equipped with a PEG shell, the nanocarriers displayed good stability and can be internalized by a variety of cancer cell lines via the lipid raft and clathrin-mediated endocytotic pathway without premature leakage, which showed a high synergetic activity of CPT and Dox toward various cancer cells. In vivo study validated that the nanocarriers exhibited strong accumulation in tumor sites and showed a prominent anticancer activity against the lung cancer xenograft mice model compared with free drugs.}, number={25}, journal={BIOMATERIALS}, author={Tai, Wanyi and Mo, Ran and Lu, Yue and Jiang, Tianyue and Gu, Zhen}, year={2014}, month={Aug}, pages={7194–7203} }
 @article{jiang_mo_bellotti_zhou_gu_2014, title={Molecule Drugs for Enhanced Therapeutic Efficacy}, volume={24}, ISSN={["1616-3028"]}, DOI={10.1002/adfm.201303222}, abstractNote={A programmed drug‐delivery system that can transport different anticancer therapeutics to their distinct targets holds vast promise for cancer treatment. Herein, a core–shell‐based “nanodepot” consisting of a liposomal core and a crosslinked‐gel shell (designated Gelipo) is developed for the sequential and site‐specific delivery (SSSD) of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) and doxorubicin (Dox). As a small‐molecule drug intercalating the nuclear DNA, Dox is loaded in the aqueous core of the liposome, while TRAIL, acting on the death receptor (DR) on the plasma membrane, is encapsulated in the outer shell made of crosslinked hyaluronic acid (HA). The degradation of the HA shell by HAase that is concentrated in the tumor environment results in the rapid extracellular release of TRAIL and subsequent internalization of the liposomes. The parallel activity of TRAIL and Dox show synergistic anticancer efficacy. The half‐maximal inhibitory concentration (IC50) of TRAIL and Dox co‐loaded Gelipo (TRAIL/Dox‐Gelipo) toward human breast cancer (MDA‐MB‐231) cells is 83 ng mL–1 (Dox concentration), which presents a 5.9‐fold increase in the cytotoxicity compared to 569 ng mL–1 of Dox‐loaded Gelipo (Dox‐Gelipo). Moreover, with the programmed choreography, Gelipo significantly improves the inhibition of the tumor growth in the MDA‐MB‐231 xenograft tumor animal model.}, number={16}, journal={ADVANCED FUNCTIONAL MATERIALS}, author={Jiang, Tianyue and Mo, Ran and Bellotti, Adriano and Zhou, Jianping and Gu, Zhen}, year={2014}, month={Apr}, pages={2295–2304} }
 @article{mo_jiang_gu_2014, title={Recent progress in multidrug delivery to cancer cells by liposomes}, volume={9}, ISSN={["1748-6963"]}, DOI={10.2217/nnm.14.62}, abstractNote={NanomedicineVol. 9, No. 8 EditorialRecent progress in multidrug delivery to cancer cells by liposomesRan Mo, Tianyue Jiang & Zhen GuRan MoJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USAMolecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USAState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, ChinaSearch for more papers by this author, Tianyue JiangJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USAMolecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USAState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, ChinaSearch for more papers by this author & Zhen GuAuthor for correspondence: E-mail Address: zgu@email.unc.eduJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USAMolecular Pharmaceutics Division, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USASearch for more papers by this authorPublished Online:14 Aug 2014https://doi.org/10.2217/nnm.14.62AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: chemotherapyco-deliverycombination cancer therapydrug deliverygene therapyliposomeprotein therapyReferences1 Bangham AD, Standish MM, Watkins JC et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13(1), 238–252 (1965).Crossref, Medline, CAS, Google Scholar2 Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine 8(9), 1509–1528 (2013).Link, CAS, Google Scholar3 Wang B, Galliford CV, Low PS. Guiding principles in the design of ligand-targeted nanomedicines. Nanomedicine 9(2), 313–330 (2014).Link, CAS, Google Scholar4 Mayer LD, Harasym TO, Tardi PG et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5(7), 1854–1863 (2006).Crossref, Medline, CAS, Google Scholar5 Batist G, Gelmon KA, Chi KN et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 15(2), 692–700 (2009).Crossref, Medline, CAS, Google Scholar6 Feldman EJ, Lancet JE, Kolitz JE et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 29(8), 979–985 (2011).Crossref, Medline, CAS, Google Scholar7 Feldman EJ, Kolitz JE, Trang JM et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk. Res. 36(10), 1283–1289 (2012).Crossref, Medline, CAS, Google Scholar8 Wong MY, Chiu GN. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine 7(6), 834–840 (2011).Crossref, Medline, CAS, Google Scholar9 Zucker D, Andriyanov AV, Steiner A et al. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy. J. Controlled Release 160(2), 281–289 (2012).Crossref, Medline, CAS, Google Scholar10 Ong JC, Sun F, Chan E. Development of stealth liposome coencapsulating doxorubicin and fluoxetine. J. Liposome Res. 21(4), 261–271 (2011).Crossref, Medline, CAS, Google Scholar11 Sawant RR, Vaze OS, Rockwell K, Torchilin VP..Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery. Eur. J. Pharm. Biopharm. 75(3), 321–326 (2010).Crossref, Medline, CAS, Google Scholar12 Maitani Y, Saito H, Seishi Y et al. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse. J. Drug Target. 20(10), 873–882 (2012).Crossref, Medline, CAS, Google Scholar13 Zhang YF, Wang JC, Bian DY et al. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur. J. Pharm. Biopharm. 74(3), 467–473 (2010).Crossref, Medline, CAS, Google Scholar14 Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18(9), 1650–1656 (2010).Crossref, Medline, CAS, Google Scholar15 Shim G, Han SE, Yu YH et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J. Controlled Release 155(1), 60–66 (2011).Crossref, Medline, CAS, Google Scholar16 Kang SH, Cho HJ, Shim G et al. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm. Res. 28(12), 3069–3078 (2011).Crossref, Medline, CAS, Google Scholar17 Xiao W, Chen X, Yang L et al. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int. J. Pharm. 393(1–2), 119–126 (2010).Crossref, Medline, CAS, Google Scholar18 Zhang Y, Schwerbrock NMJ, Rogers AB et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. 21(8), 1559–1569 (2013).Crossref, Medline, CAS, Google Scholar19 Zhang M, Garbuzenko OB, Reuhl KR, Rodriguez-Rodriguez L, Minko T., Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine 7(2), 185–197 (2012).Link, CAS, Google Scholar20 Sochanik A, Mitrus I, Smolarczyk R et al. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent. Arch. Immunol. Ther. Exp. (Warsz) 58(3), 235–245 (2010).Crossref, Medline, CAS, Google Scholar21 Koo YT, Falcao C, Torchilin VP. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol. Pharm. 6(3), 971–977 (2009).Crossref, Medline, Google Scholar22 Jiang T, Mo R, Bellotti A et al. Gel-liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy. Adv. Funct. Mater. 24(16), 2295–2304 (2014).Crossref, CAS, Google Scholar23 Wu GH, Milkhailovsky A, Khant HA et al. Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. J. Am. Chem. Soc. 130(26), 8175–8177 (2008).Crossref, Medline, CAS, Google Scholar24 Mo R, Jiang T, Gu Z. Enhanced anticancer efficacy by ATP-mediated liposomal. drug delivery. Angew. Chem. Int. Ed. 53(23), 5815–5820 (2014).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByEngineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applicationsBiotechnology Advances, Vol. 67Engineered Extracellular Vesicles with Compound-Induced Cargo Delivery to Solid Tumors27 May 2023 | International Journal of Molecular Sciences, Vol. 24, No. 11ZnO Nanorods Create a Hypoxic State with Induction of HIF-1 and EPAS1, Autophagy, and Mitophagy in Cancer and Non-Cancer Cells9 April 2023 | International Journal of Molecular Sciences, Vol. 24, No. 8Amphiphilic Polypeptides Obtained by Post-Polymerization Modification of Poly-l-Lysine as Systems for Combined Delivery of Paclitaxel and siRNA21 April 2023 | Pharmaceutics, Vol. 15, No. 4Lipid Nanocarriers for Breast Cancer Treatment14 December 2022pH-Responsive Drug Delivery Nanoplatforms as Smart Carriers of Unsymmetrical Bisacridines for Targeted Cancer Therapy6 January 2023 | Pharmaceutics, Vol. 15, No. 1Chitosan-Boric Acid Scaffolds for Doxorubicin Delivery in the Osteosarcoma Treatment6 November 2022 | Polymers, Vol. 14, No. 21Nanocarriers for intracellular co-delivery of proteins and small-molecule drugs for cancer therapy6 September 2022 | Frontiers in Bioengineering and Biotechnology, Vol. 10Congo Red as a Supramolecular Carrier System for Doxorubicin: An Approach to Understanding the Mechanism of Action11 August 2022 | International Journal of Molecular Sciences, Vol. 23, No. 16Carbohydrates based stimulus responsive nanocarriers for cancer-targeted chemotherapy: a review of current practices8 June 2022 | Expert Opinion on Drug Delivery, Vol. 19, No. 6Composite Materials Based on Gelatin and Iron Oxide Nanoparticles for MRI Accuracy12 May 2022 | Materials, Vol. 15, No. 10Zinc Oxide Nanoparticles Ameliorate Dimethylnitrosamine-Induced Renal Toxicity in Rat2 December 2021 | Applied Biochemistry and Biotechnology, Vol. 194, No. 4Multifunctional carbon dot anchored halloysite nanotube: Nanovehicle for cisplatin drug release, cytotoxicity on breast cancer cells and DNA binding studiesChemical Data Collections, Vol. 38Doxorubicin Release from Bovine Serum Albumin Microparticles11 February 2022 | Pharmaceutical Chemistry Journal, Vol. 55, No. 11A review of Nigella sativa and its active principles as anticancer agentsPlant Pollen Grains: A Move Towards Green Drug and Vaccine Delivery Systems15 May 2021 | Nano-Micro Letters, Vol. 13, No. 1Autonomously Propelled Colloids for Penetration and Payload Delivery in Complex Extracellular Matrices6 October 2021 | Micromachines, Vol. 12, No. 10Polymer incorporated magnetic nanoparticles: Applications for magnetoresponsive targeted drug deliveryMaterials Science and Engineering: B, Vol. 272A DFT Study of Graphitic Carbon Nitride as Drug Delivery Carrier for Flutamide (Anticancer Drug)21 June 2021 | Journal of Computational Biophysics and Chemistry, Vol. 20, No. 04Lignin, lipid, protein, hyaluronic acid, starch, cellulose, gum, pectin, alginate and chitosan-based nanomaterials for cancer nanotherapy: Challenges and opportunitiesInternational Journal of Biological Macromolecules, Vol. 178Delivery of eupenifeldin via polymer-coated surgical buttresses prevents local lung cancer recurrenceJournal of Controlled Release, Vol. 331Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics26 January 2021 | Biomedicines, Vol. 9, No. 2Material and strategies used in oncology drug deliveryAlginate-based hydrogels as drug delivery vehicles in cancer treatment and their applications in wound dressing and 3D bioprinting13 March 2020 | Journal of Biological Engineering, Vol. 14, No. 1In-vitro and in-vivo evaluation of polymeric microsphere formulation for colon targeted delivery of 5-fluorouracil using biocompatible natural gum katiraInternational Journal of Biological Macromolecules, Vol. 158Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than DoxilⓇAsian Journal of Pharmaceutical Sciences, Vol. 15, No. 3pH-responsive nanomicelles of poly(ethylene glycol)-poly(ε-caprolactone)-poly(L-histidine) for targeted drug delivery11 November 2019 | Journal of Biomaterials Science, Polymer Edition, Vol. 31, No. 3Bifidobacterium spp: the promising Trojan Horse in the era of precision oncologyNealie Ngo, Khalil Choucair, Justin F Creeden, Hanan Qaqish, Krupa Bhavsar, Chantal Murphy, Kendra Lian, Mary T Albrethsen, Laura Stanbery, Richard C Phinney, F Charles Brunicardi, Lance Dworkin & John Nemunaitis31 October 2019 | Future Oncology, Vol. 15, No. 33Understanding the Nano-bio Interfaces: Lipid-Coatings for Inorganic Nanoparticles as Promising Strategy for Biomedical Applications15 May 2019 | Frontiers in Chemistry, Vol. 7Recent Advances in Chitosan-Based Systems for Delivery of Anticancer Drugs6 March 2020Combinational delivery therapies of nucleic acids for cancer treatmentDual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance11 March 2019 | Drug Delivery, Vol. 26, No. 1Controlled drug delivery vehicles for cancer treatment and their performance16 March 2018 | Signal Transduction and Targeted Therapy, Vol. 3, No. 1Recent Advances in Self-assembled Nano-therapeutics26 December 2017 | Chinese Journal of Polymer Science, Vol. 36, No. 3Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine2 October 2017 | AAPS PharmSciTech, Vol. 19, No. 2Liposome-targeted delivery for highly potent drugs17 February 2017 | Artificial Cells, Nanomedicine, and Biotechnology, Vol. 45, No. 8Liposome-Coated Persistent Luminescence Nanoparticles as Luminescence Trackable Drug Carrier for Chemotherapy15 June 2017 | Analytical Chemistry, Vol. 89, No. 13Zinc oxide nanoparticles antagonize the effect of Cetuximab on head and neck squamous cell carcinoma in vitro11 May 2017 | Cancer Biology & Therapy, Vol. 18, No. 7Nanoformulations for combination or cascade anticancer therapyAdvanced Drug Delivery Reviews, Vol. 115Liposome-based drug co-delivery systems in cancer cellsMaterials Science and Engineering: C, Vol. 71Zinc oxide nanoparticles as a novel anticancer approach; in vitro and in vivo evidence24 January 2017 | Clinical and Experimental Pharmacology and Physiology, Vol. 44, No. 2Nanoscale Drugs: A Key to Revolutionary Progress in Pharmacy and Healthcare2 December 2016Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy1 January 2017 | Biomaterials Science, Vol. 5, No. 8DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting17 October 2016 | Drug Delivery, Vol. 23, No. 9Co-delivery of drugs and plasmid DNA for cancer therapyAdvanced Drug Delivery Reviews, Vol. 98Co-delivery of chemotherapeutics and proteins for synergistic therapyAdvanced Drug Delivery Reviews, Vol. 98Recent advances of cocktail chemotherapy by combination drug delivery systemsAdvanced Drug Delivery Reviews, Vol. 98A poly(ascorbyl acrylate)-containing nanoplatform with anticancer activity and the sequential combination therapy with its loaded paclitaxel1 January 2016 | Journal of Materials Chemistry B, Vol. 4, No. 40Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatmentBiomaterials, Vol. 73Furin-Mediated Sequential Delivery of Anticancer Cytokine and Small-Molecule Drug Shuttled by Graphene15 December 2014 | Advanced Materials, Vol. 27, No. 6Development of individualized anti-metastasis strategies by engineering nanomedicines1 January 2015 | Chemical Society Reviews, Vol. 44, No. 17Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells1 January 2015 | Journal of Materials Chemistry B, Vol. 3, No. 8 Vol. 9, No. 8 STAY CONNECTED Metrics Downloaded 458 times History Published online 14 August 2014 Published in print June 2014 Information© Future Medicine LtdKeywordschemotherapyco-deliverycombination cancer therapydrug deliverygene therapyliposomeprotein therapyFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download}, number={8}, journal={NANOMEDICINE}, author={Mo, Ran and Jiang, Tianyue and Gu, Zhen}, year={2014}, month={Jun}, pages={1117–1120} }
 @article{jiang_sun_zhu_burns_khan_mo_gu, title={Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene}, volume={27}, number={6}, journal={Advanced Materials}, author={Jiang, T. Y. and Sun, W. J. and Zhu, Q. W. and Burns, N. A. and Khan, S. A. and Mo, R. and Gu, Z.}, pages={1021–1028} }